ReviewBreast care (Basel, Switzerland)2017
Prophylactic Surgery: For Whom, When and How?
Review in Breast care (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2021Pooled it
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Article
- Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Drug-Eluting Sutures by Hot-Melt Extrusion: Current Trends and Future Potentials.Materials (Basel, Switzerland) · 2023Review
- Evaluation of disparities in perceived healthcare discrimination amongWomen & health · 2023Article
- Residential Locale Is Associated with Disparities in Genetic Testing-Related Outcomes Among BRCA1/2-Positive Women.Journal of racial and ethnic health disparities · 2023Article
- EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.European journal of cancer (Oxford, England : 1990) · 2023Review
- The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery inCurrent oncology (Toronto, Ont.) · 2023Review
- A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.Acta bio-medica : Atenei Parmensis · 2022Article
- Anxiety and depression among racial/ethnic minorities and impoverished women testing positive for BRCA1/2 mutations in the United States.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.Gynecologic oncology reports · 2022Article
- COVID-19 experiences predicting high anxiety and depression among a sample of BRCA1/BRCA2-positive women in the US.Scientific reports · 2021Article
- Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.Breast cancer (Tokyo, Japan) · 2021Article
- COVID-19 Experiences Predicting High Anxiety and Depression Among a Sample of BRCA1/BRCA2-positive Women in the US.Research square · 2021Article
- Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.Geburtshilfe und Frauenheilkunde · 2021Article
- Quality of Life After Bilateral Risk-Reducing Mastectomy and Simultaneous Reconstruction Using Pre-Pectoral Silicone Implants.Patient preference and adherence · 2021Article
- Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.Breast cancer research and treatment · 2020Article
- Surgery forEcancermedicalscience · 2018Review
- Mastectomy - Current Challenges and Questions.Breast care (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk-reducing surgery has proved to be a reasonable procedure in healthy women with a definitely elevated risk of developing cancer. Here we consider the elevated risk of breast and ovarian cancer. There is a clear indication for such surgery in healthy women with a pathogenic BRCA1/2 mutation. For these patients, a risk-reducing bilateral mastectomy leads to a verifiable reduction in mortality from breast cancer, particularly for young patients. In most cases, surgery is combined with breast reconstruction. The pros and cons of surgical treatment and the different surgical techniques have to be explained to and carefully considered with the patient. As yet, no unequivocal data for the benefits of intensifying early detection have been ascertained with respect to mortality from breast carcinoma. In index patients with a BRCA mutation, the surgical treatment should depend on the prognosis of the primary disease. A lower age at onset and a better prognosis of the primary disease make a contralateral mastectomy (CPM) more reasonable. In the case of BRCA mutation-related cancer, a reduction of mortality through CPM has been proven. A risk-reducing adnexectomy is basically recommended for BRCA mutation carriers. Healthy premenopausal women need a subsequent hormone replacement therapy. The prognosis of the patients is dominated by the ovarian carcinoma. This can be prevented by risk-reducing salpingo-oophorectomy in 95% of the cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.